435 related articles for article (PubMed ID: 16318984)
1. Immunotherapy for the prevention and treatment of type 1 diabetes.
Goudy KS; Tisch R
Int Rev Immunol; 2005; 24(5-6):307-26. PubMed ID: 16318984
[TBL] [Abstract][Full Text] [Related]
2. Antigen-specific induction of regulatory T cells for type 1 diabetes therapy.
Filippi C; Bresson D; von Herrath M
Int Rev Immunol; 2005; 24(5-6):341-60. PubMed ID: 16318986
[TBL] [Abstract][Full Text] [Related]
3. Achieving antigen-specific tolerance in diabetes: regulating specifically.
Chen W; Bluestone JA; Herold KC
Int Rev Immunol; 2005; 24(5-6):287-305. PubMed ID: 16318983
[TBL] [Abstract][Full Text] [Related]
4. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment.
You S; Leforban B; Garcia C; Bach JF; Bluestone JA; Chatenoud L
Proc Natl Acad Sci U S A; 2007 Apr; 104(15):6335-40. PubMed ID: 17389382
[TBL] [Abstract][Full Text] [Related]
5. Transfusion of apoptotic beta-cells induces immune tolerance to beta-cell antigens and prevents type 1 diabetes in NOD mice.
Xia CQ; Peng R; Qiu Y; Annamalai M; Gordon D; Clare-Salzler MJ
Diabetes; 2007 Aug; 56(8):2116-23. PubMed ID: 17496235
[TBL] [Abstract][Full Text] [Related]
6. The type and frequency of immunoregulatory CD4+ T-cells govern the efficacy of antigen-specific immunotherapy in nonobese diabetic mice.
Pop SM; Wong CP; He Q; Wang Y; Wallet MA; Goudy KS; Tisch R
Diabetes; 2007 May; 56(5):1395-402. PubMed ID: 17317763
[TBL] [Abstract][Full Text] [Related]
7. CD3-specific antibodies: a portal to the treatment of autoimmunity.
Chatenoud L; Bluestone JA
Nat Rev Immunol; 2007 Aug; 7(8):622-32. PubMed ID: 17641665
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms mediating anti-CD3 antibody efficacy: insights from a mathematical model of type 1 diabetes.
Young DL; Ramanujan S; Kreuwel HT; Whiting CC; Gadkar KG; Shoda LK
Ann N Y Acad Sci; 2006 Oct; 1079():369-73. PubMed ID: 17130581
[TBL] [Abstract][Full Text] [Related]
9. Role of regulatory T cells for the treatment of type 1 diabetes mellitus.
Jaeckel E; Mpofu N; Saal N; Manns MP
Horm Metab Res; 2008 Feb; 40(2):126-36. PubMed ID: 18283631
[TBL] [Abstract][Full Text] [Related]
10. Disease-modifying immunotherapy for the management of autoimmune diabetes.
Castro CN; Barcala Tabarrozi AE; Noguerol MA; Liberman AC; Dewey RA; Arzt E; Morelli AE; Perone MJ
Neuroimmunomodulation; 2010; 17(3):173-6. PubMed ID: 20134195
[TBL] [Abstract][Full Text] [Related]
11. CD8+ T cells in type 1 diabetes.
Tsai S; Shameli A; Santamaria P
Adv Immunol; 2008; 100():79-124. PubMed ID: 19111164
[TBL] [Abstract][Full Text] [Related]
12. Do immunotherapy and beta cell replacement play a synergistic role in the treatment of type 1 diabetes?
Li DS; Warnock GL; Tu HJ; Ao Z; He Z; Lu H; Dai LJ
Life Sci; 2009 Oct; 85(15-16):549-56. PubMed ID: 19747492
[TBL] [Abstract][Full Text] [Related]
13. Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy.
Tian B; Hao J; Zhang Y; Tian L; Yi H; O'Brien TD; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2009 Jan; 87(2):198-206. PubMed ID: 19155973
[TBL] [Abstract][Full Text] [Related]
14. The natural killer T lymphocyte: a player in the complex regulation of autoimmune diabetes in non-obese diabetic mice.
Cardell SL
Clin Exp Immunol; 2006 Feb; 143(2):194-202. PubMed ID: 16412042
[TBL] [Abstract][Full Text] [Related]
15. beta cell-specific CD4+ T cell clonotypes in peripheral blood and the pancreatic islets are distinct.
Li L; He Q; Garland A; Yi Z; Aybar LT; Kepler TB; Frelinger JA; Wang B; Tisch R
J Immunol; 2009 Dec; 183(11):7585-91. PubMed ID: 19917704
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.
Ishikawa H; Ochi H; Chen ML; Frenkel D; Maron R; Weiner HL
Diabetes; 2007 Aug; 56(8):2103-9. PubMed ID: 17456848
[TBL] [Abstract][Full Text] [Related]
17. Gene delivery GAD 500 autoantigen by AAV serotype 1 prevented diabetes in NOD mice: transduction efficiency do not play important roles.
Han G; Wang R; Chen G; Wang J; Xu R; Feng J; Yu M; Wu X; Qian J; Shen B; Li Y
Immunol Lett; 2008 Jan; 115(2):110-6. PubMed ID: 18045698
[TBL] [Abstract][Full Text] [Related]
18. New prospects for immunotherapy at diagnosis of type 1 diabetes.
Pozzilli P; Leslie RD
Diabetes Metab Res Rev; 2009 May; 25(4):299-301. PubMed ID: 19405079
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of type 1 diabetes.
Li L; Yi Z; Tisch R; Wang B
Arch Immunol Ther Exp (Warsz); 2008; 56(4):227-36. PubMed ID: 18726144
[TBL] [Abstract][Full Text] [Related]
20. The role of low avidity T cells in the protection against type 1 diabetes: a modeling investigation.
Khadra A; Santamaria P; Edelstein-Keshet L
J Theor Biol; 2009 Jan; 256(1):126-41. PubMed ID: 18950644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
